Opus Genetics

Opus Genetics says its mission is to restore and preserve vision for patients with inherited retinal diseases. The company describes its team as hands-on and growing, and says it values ownership, curiosity, and momentum.

Cam Gallagher has more than 30 years of experience in life sciences and biotech, focusing on company formation, corporate development, marketing, operations, and early-stage investing. He has served on the Ocuphire (now Opus) Board since January 2019 and as chair since December 2019.

Chris has more than 30 years of industry experience, including laboratory operations management and oversight of phase I–IV clinical research across pharmaceuticals, biologics, gene therapies, combination products, and medical devices.

Dr. Bennett is the F.M. Kirby Emeritus Professor of Ophthalmology at the Perelman School of Medicine, previously directed the Center for Advanced Retinal and Ocular Therapeutics (CAROT) at the University of Pennsylvania, and has been an Investigator at the Center.

Sally Tucker is an independent prescribing optometrist with a PhD in ophthalmology and a master’s in business management. Sally joined the ophthalmology industry in 2003 and has more than 20 years’ experience across sales and marketing, training, medical affairs and clinical work.

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases. Its mission is to address the genetic causes of severe retinal disorders and deliver durable vision improvement.

Opus Genetics 8 Davis DriveDurham, NC 27713 To receive email alerts from Opus, register here. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment of IRDs and other retinal and refractive disorders.